Opportunities for Data Science in the Pharmaceutical Industry: The Use of Data to Find Efficiencies in Drug Development Can?t Come Too Soon
| Autor: | Nirmal Keshava |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Drug Industry United States Food and Drug Administration business.industry Research Statistics as Topic Biomedical Engineering General Medicine 030105 genetics & heredity United States Biotechnology Food and drug administration 03 medical and health sciences Agricultural science Drug development Return on investment Humans Medicine business Drug industry Pharmaceutical industry |
| Zdroj: | IEEE Pulse. 8:10-14 |
| ISSN: | 2154-2317 2154-2287 |
| DOI: | 10.1109/mpul.2017.2678638 |
| Popis: | By the numbers, 2016 was not a good year for the U.S. pharmaceutical industry. As of early December, only 19 new drugs had been approved by the Food and Drug Administration (FDA), fewer than half of those approved in 2015 and the lowest number since 2007. Further, the FDA approved only 61% of submissions in 2016, compared to 95% in 2015 [1]. And, among the largest companies, the return on investment for research and development (R&D) fell to 3.7% [2]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|